Jeroen Tas is Chief Innovation & Strategy Officer and member of the Executive Committee at Royal Philips. He has more than 30 years of global experience as an entrepreneur and executive in the healthcare, information technology and financial services industries.

Jeroen is responsible for the company’s strategy, research & development, design, medical affairs, sustainability, platforms and emerging businesses. As Chief Innovations & Strategy Officer he plays a central role in the transition of Philips to a customer-centric digital solutions company. He will leverage emerging technologies such as artificial intelligence, robotics and the Internet of Things to reinforce the company’s health propositions aimed at supporting consumers, care professionals and health systems with personalized connected health solutions. Jeroen’s stance is echoed in Philips’ commitment to touch the lives of billions and improve better health outcomes at lower cost: from healthy living and prevention to diagnosis, treatment and home care. Earlier in his career Jeroen was co-founder of the IT company Mphasis and served as President, COO and Vice Chairman. He ran the Technology Lab at Citigroup and launched Internet banking in the mid-nineties.

Working together with public and private players in the healthcare field to achieve sustainable access to innovative medicines.

Space for more info

Nicholas has almost 20 years’ experience in the Healthcare industry. He moved to Stifel as a Managing Director on the Healthcare Investment Banking team in January 2018 to continue to focus on delivering equity financing solutions to Europe-based healthcare companies, but also with a broader remit across M&A and strategic advice.

Moore joined Morgan Stanley’s Healthcare Investment Banking Team in 2006, where he worked on a number of M&A and capital markets transactions. In early 2011, Nicholas moved to the Equity Capital Markets team at Jefferies in London, where he initially focused on raising equity capital across industries within the broader EMEA region. In December 2013, Nicholas was named as one of the Top 40 Under 40 Rising Stars in Investment Banking by Financial News, partly in recognition of the more than 20 equity capital markets transactions he completed in 2013 alone. Since mid-2013, Nicholas focused on raising equity capital for European healthcare companies, especially those companies in the biopharma subsector targeting investment from U.S.-based healthcare specialist investors. In January 2018, Nicholas moved to Stifel as a Managing Director on the Healthcare Investment Banking team to continue to focus on delivering equity financing solutions to Europe-based healthcare companies, but also with a broader remit across M&A and strategic advice.

Anne Portwich, PhD, is a Partner at LSP, a European investment firm, providing financing for private and public life sciences companies. Since the late 1980s, the LSP team has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry.

With over €1.7 billion ($2.0 billion) of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is Europe’s leading life sciences investor. Over the years, Anne has been responsible for investments in numerous portfolio companies of LSP, such as Sapiens (acquired by Medtronic in 2014), Nexstim (IPO in 2014), and ActoGeniX (acquired by Intrexon in 2015). When the first LSP Health Economics Fund was launched in 2012, she became part of the investment team managing this fund, leading investments in companies such as ViCentra, Mint Solutions, Vivasure Medical and Neuravi (acquired by Codman Neuro in 2017). She also played an essential role in raising LSP Health Economics Fund 2 in 2017, the largest European fund dedicated to medical technology with a fund size of EUR 280 million. Prior to joining LSP, Anne was a Scientist and Project Leader at OctoPlus, a Dutch company offering advanced research services to pharmaceutical and biotechnology companies. She obtained an MSc in biochemistry from the University of Hanover and received her PhD from the Max Planck-Institute of Marine Microbiology in Bremen.

Martin van der Graaff is currently Secretary of the Scientific Advisory Board (WAR) of the Dutch National Health Care Institute. He spent 11 years in R&D at Organon and Solvay Pharma, followed by 12 years at Nefarma until he made the transition to the public sector.

Van der Graaff studied Pharmacy and received his Ph.D. from Leiden University. At Organon and Solvay Pharma, he covered subjects such as lyophilization, injection formulation, human pharmacokinetics and bioequivalence, preclinical development studies, and toxicology. He then moved on to the association of the innovative pharmaceutical industry, Nefarma. For 12 years he was, in different positions, responsible for subjects ranging from regulatory and registration issues, biotechnology, environmental issues, to orphan drugs and sustainable development. In 2008 he changed track from the private to the public sector and joined the Dutch Healthcare Insurance Board (CVZ). The constant factor in his professional life has always been the drive to supply patients with the best possible treatments, and, where feasible and sustainable, even better ones.

Ewoud Welten, Msc. (M), joined Biocartis as Chief Financial Officer in September 2015. Coming from international investment bank Kempen & Co where he worked as Vice President Corporate Finance, he has a proven track record in the Life Sciences and Healthcare sector as a corporate financier, in which position he managed numerous international capital markets transactions including IPOs, secondary fundraisings and M&A transactions.

Ewoud holds a Master Degree in Financial Economics (distinction) from the Erasmus University Rotterdam, the Netherlands.

Peter connects patients, researchers and clinicians to further research, treatments and care; in the Netherlands as well as internationally. He was diagnosed with cancer in the lymph nodes in 2005, and is the driving force behind Inspire2Live.

Inspire2Live is convinced that we can get cancer under control by the cooperation of patients, researchers and clinicians and with the combination of emotions and arguments. Peter organizes congresses, lobbies the matrix of public authorities, health care organizations, insurance companies and health research institutes. He also give lectures and talks to help patients and society to fight cancer where possible and live with cancer with a good quality of life. He is a writer of blogs, articles and books that also contributes to these topics. Peter works at the Central Bank of the Netherlands as a program manager and advisor for complex and politically difficult problems. His employer facilitates him in his patient advocacy. Peter was honored with a doctorate in October 2012 at the Free University in Amsterdam for connecting patients, researchers and clinicians all over the world.

Cornelis Boersma, PhD, is the founder & CEO of Health-Ecore BV. He has over 15 years of experience in the healthcare sector, combining science, policy & entrepreneurship with the ambition to achieve high quality, accessible and affordable healthcare in collaboration with private and public parties.

At GSK, Boersma held various roles, including Head of Market Access for Europe & Canada, Head of Global Franchises Communications & Government Affairs and Director Corporate Affairs. Boersma is also affiliated with the University of Groningen as a visiting researcher. In his view, investments in optimal and sustainable health(care) yield a great opportunity from an economical and societal perspective. Here, it is important to find the right balance between access for all, affordability and reward for innovation.

Wieteke Wouters is programme director of HollandBIO, the Dutch biotech industry association. HollandBIO unites and supports a growing member base of over 175 companies in their ambitions to deliver biotech innovations that contribute to our society’s health, sustainability and economic growth.

Prior to joining HollandBIO, Wieteke was responsible for the Life Sciences & Health activities of consultancy firm Schuttelaar & Partners, working for many different stakeholders in the biotech sector. Wieteke began her career in various roles at genomics service provider ServiceXS (now Genomescan). Wieteke graduated in Biomedical Sciences at Utrecht University and specialized in Science and Business Management.

Dr. Markwin Velders brings over 18 years of management experience in biotechnology companies. He obtained his PhD from Leiden University in 1996. After a post-doc and associate professorship at Loyola University in Chicago, he became Chief Scientific Officer at AM-Pharma in 2004.

After bringing two compounds from bench to bed at AM-Pharma, Markwin moved to TNO Biosciences as a Business Unit Manager, managing a group of 150 professionals. Since 2011 he has been independently active as Prime Life Science, assisting various start-up and early life science companies with their strategy, financing, business development and interim management. He has been involved in the start-up of several new ventures, and secured funding for 4 Life Science start-ups.
End of 2013 Markwin became involved with a potential start up from the Netherland’s Cancer Institute (NKI) that was incorporated in 2014 and called T-cell Factory (TCF). Subsequently, he was instrumental in the M&A deal where Kite Pharma Inc. acquired TCF to form Kite Pharma EU B.V. Since March 2015 he is Vice President Operations and Managing Director of Kite Pharma EU B.V. in Amsterdam. As of June 2017 Markwin is chairman of the board of HollandBio, the branch association for Biotech in the Netherlands.

Heyning studied applied physics at the Technical University of Delft. He was awarded a scholarship in an honours program and graduated Cum Laude for masters Applied Physics, minor in Economics in 2006. He set up LUMICKS with the aim to take novel breakthrough technology developed at the VU University in Amsterdam successfully to the market.

After having lived in Shanghai, where he worked in sourcing, Olivier joined FEI Company (now ThermoFisher), a manufacturer of electron microscopes. Here, Olivier managed large international teams in Sales, Service and operations, and Global Business Development.
Having gained enough business experience, Olivier switched to entrepreneurship and set up LUMICKS, with the aim to take novel breakthrough technology developed at the VU University in Amsterdam successfully to the market. He built a team and company producing high-tech optical instruments that enable Dynamic Single-molecule analysis (DSM). The ability to film and measure biological and disease processes at the level of individual molecules interacting is a breakthrough for biologists and pharmacologists who need to unravel the complex mechanistic details of these interactions to better understand life and for more effective drug discovery.
LUMICKS is now a successful business with 50 employees, offices in Amsterdam and Boston, and a global team supporting its customers in all corners of the world: from UC Berkeley to Max Planck to ShanghaiTech.

The Vereniging Innovatieve Geneesmiddelen is the industry association for the Dutch branches of innovative pharmaceutical companies. It supports their 44 members in their ambitions to deliver (bio) pharmaceuticals that help the right patients at the right time, but also to be an important stakeholder in sustainability, health and economic growth of the Netherlands.

Prior to joining the Association Innovative Medicines Carla has 20 years of management experience in the innovative medicines sector, working with several stakeholders in the sector. In 1998 she joined MSD and started at the clinical research department. She moved to the leadership team of MSD in 2008 as Director External Affairs (Market Access, Policy and Communication). Subsequently she fulfilled roles within Sales & Marketing, strategic account management and Commercial Operations. She believes that medicines are of great value to healthcare and society and that the contribution by innovative pharmaceutical companies has a huge impact on patients. In her time at MSD she experienced that lethal diseases became chronic while still obtaining a very good quality of live for patients Besides the Association she is also commission member at ZonMw for the program Optimal use of Medicines (Goed Geneesmiddelen Gebruik). Carla graduated as health scientist at the University of Maastricht and obtained her PhD from Leiden University in 2001.

Connect with Martine on LinkedIn or check out her CV.

Connect with Rebecca on LinkedIn or check out her CV.

Check out Roel’s CV.

Check out Jan’s CV.

Check out Henk Arnold’s CV.

Check out Adam’s CV.

Check out Mirjam’s CV.